The prevalence of obesity has increased worldwide, and therefore, the burden of obesity on health is progressively growing ([@B1]). Obesity is associated with insulin resistance and an increased risk of type 2 diabetes. Recently, it has become clear that obesity promotes a state of chronic, low-grade inflammation in white adipose tissue (WAT), which leads to insulin resistance. Adipocytes and macrophages in WAT both are involved in the development of insulin resistance in obesity through the release of free fatty acids (FFAs), proinflammatory cytokines, and adipokines ([@B2]--[@B4]).

Resistin, predominantly expressed in adipocytes, mediates insulin resistance in rodents. Circulating levels of resistin are increased in obesity, and treatment with recombinant resistin or transgenic overexpression of resistin induces hepatic insulin resistance in mice ([@B5]--[@B8]). Furthermore, deletion of resistin enhances insulin sensitivity in livers of mice fed a high-fat diet, and in muscle and WAT in leptin-deficient *ob/ob* mice ([@B9],[@B10]). In contrast, resistin is mainly expressed in mononuclear cells, including macrophages in humans ([@B11],[@B12]). Human resistin is induced in response to various inflammatory stimuli such as lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), or interleukin (IL)-6, and resistin itself induces proinflammatory cytokines, suggesting a role for resistin in inflammation in humans ([@B13]--[@B16]). Moreover, circulating resistin levels correlate with inflammatory markers in subjects with type 2 diabetes, coronary atherosclerosis, chronic kidney disease, rheumatoid arthritis, sepsis, and experimental endotoxemia ([@B14],[@B17]--[@B21]).

Because it is widely accepted that obesity and type 2 diabetes are associated with chronic inflammation in WAT, and resistin is produced by macrophages in inflammation, hyperresistinemia might be a contributing factor to these pathophysiologic states in humans. However, studies relating resistin in humans to obesity, insulin resistance, or type 2 diabetes have shown conflicting results ([@B22]--[@B28]). Therefore, it remains uncertain whether the role of adipocyte-derived murine resistin in glucose homeostasis translates directly to the biology of macrophage-derived human resistin.

We have previously demonstrated that transgenic expression of human resistin in resistin-knockout (*Rko*) mice fed a high-fat diet results in insulin resistance in muscle and adipose tissue, indicating that macrophage-derived human resistin exacerbates insulin resistance ([@B29]). However, macrophage human resistin expression in that model was constitutive and not induced by inflammatory stimuli. Here we investigated the metabolic effects of human resistin induced by inflammation using a novel transgenic mouse that express human resistin from its human genomic elements (*BAC-Retn* mice). In contrast to the previous macrophage-specific humanized resistin mice, circulating resistin levels in this new *BAC-Retn* mouse are similar to those in healthy humans but increase in response to inflammatory signals such as LPS. Under experimental endotoxemia, *BAC-Retn* mice showed increased inflammation and hepatic insulin resistance. Thus, with a humanized expression pattern, human resistin contributes to the development of insulin resistance in inflammation.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Cell culture and transfections. {#s6}
-------------------------------

The BAC-Retn construct that included the human resistin gene plus 20 kb upstream and 4 kb downstream DNA regions was engineered and transfected into mouse macrophage RAW.264 cells by electroporation according to the manufacturer's instructions (Lonza, Allendale, NJ). Primary mouse macrophages were obtained from male *BAC-Retn* mice by peritoneal lavage 3 days after an intraperitoneal injection with 1 mL of sterile 3% thioglycollate. RAW.264 cells or primary mouse macrophages were stimulated with LPS for 16 h. Cells or media not exposed to LPS served as the control. Human resistin gene expression was detected by quantitative PCR, and protein in the media was determined by ELISA (Millipore Corporation, Billerica, MA).

Derivation and treatment of animals. {#s7}
------------------------------------

For the derivation of mice that express the human resistin under the control of the human resistin regulatory DNA elements, we engineered a BAC as described previously ([@B30]). The engineered BAC contained the whole human resistin gene, including 21,300 bp upstream and 4,248 bp downstream of the human resistin start site. The fusion construct containing human resistin and the 25,548 bp surrounding it was then excised using *Not*I/*Bgl*II and injected into the pronucleus of fertilized C57BL/6 J mouse oocytes (Transgenic and Chimeric Mouse Facility, University of Pennsylvania). Transgenic founder mice were identified by PCR of tail DNA with the forward primer covering the 5′ end of the human resistin exon (5′-ACCAGTCTCTGGACATGAAG-3′) and the reverse primer covering the 3′-end of the human resistin exon (5′-TCGGTGGGCTCAGCTAACCA-3′). Positive mice were propagated by mating to *Retn*^−/−^ mice ([@B9]). The progeny (*Retn*^+/−^BAC*hR*) were then crossed back to the *Retn*^−/−^ mice to produce the BAC-transgenic (*BAC-Retn*) mice that express human resistin without expressing murine resistin (*Retn*^−/−^BAC*hR*). *Retn*^−/−^ littermates were used as controls in this study.

Animals used in all experiments were age-matched (10- to 12-week-old) male mice housed four or five per cage under an ambient temperature of 22°C with 12 h light/dark cycle (lights on at 0700 h). Regular chow (LabDiet, Richmond, IN) and water were provided ad libitum. All protocols for animal use and euthanasia were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania School of Medicine and were in accordance with National Institutes of Health guidelines.

LPS administration. {#s8}
-------------------

Mice were weighed to determine the dose of LPS (*Escherichia coli* O 111:B4; Sigma-Aldrich, St. Louis, MO). For acute endotoxemia experiments, equivalent volumes of LPS (0.2 mg/kg body wt) or normal saline (0.9%) were intraperitoneally injected to both *Rko* and *BAC-Retn* mice. Blood was collected before and at 1, 3, and 6 h after injection. For chronic endotoxemia experiments, mice were implanted subcutaneously with an osmotic minipump (Alzet model 1002; Braintree Scientific Inc., Braintree, MA) as previously described ([@B31]). The pumps were filled with normal saline or LPS to infuse 2 mg/kg/day for 2 weeks.

Total RNA extraction and quantitative PCR. {#s9}
------------------------------------------

Mice were killed and their tissues isolated and immediately placed in liquid nitrogen for later use. Total RNA from tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. RNA integrity was determined with ultraviolet spectrophotometry. Reverse transcription was performed with Sprint RT complete-Oligo(dT)18 (Clontech Laboratories, Mountain View, CA) according to the manufacturer's instructions. Expression of genes was analyzed using real-time (TaqMan) quantitative PCR (ABI Prism; Applied Biosystems, Foster City, CA) as previously described ([@B29]). The level of mRNA expression was normalized to 36B4.

Measurement of serum and tissue metabolites. {#s10}
--------------------------------------------

Blood glucose measurements were obtained from tail vein blood using the OneTouch Ultra Glucometer (Lifescan, Milpitas, CA). Serum was harvested by tail vein blood or cardiac puncture, spun at 4°C for 30 min, and assayed immediately or stored at −20°C. Serum alanine aminotransferase (ALT), TGs, cholesterol, β-hydroxybutyric acid, and FFAs levels were measured using colorimetric assays (Stanbio Laboratory, Boerne, TX; Wako Pure Chemical Industries, Osaka, Japan). Serum mouse insulin, resistin, leptin, high-molecular-weight adiponectin, and human resistin levels were measured by ELISA (Crystal Chem Inc., Downers Grove, IL; Millipore Corporation, Billerica, MA). Serum TNF-α and IL1β levels were measured with Luminex-100 multiplex immunoassay (Millipore). Lipids were extracted from liver for TGs and cholesterol measurements, as previously described ([@B32]). For diacylglycerol and ceramides levels, 100-mg samples of liver tissue were submitted to the Mouse Metabolic Phenotyping Center at Yale Medical School (New Haven, CT).

Glucose tolerance test. {#s11}
-----------------------

On the 8th day after the minipump subcutaneous implantation, glucose tolerance testing was performed after an 8-h fast. Blood glucose concentrations were measured before and at 15, 30, 60, 90, and 120 min after an intraperitoneal injection of glucose (1 g/kg, 20% glucose solution). Tail blood samples collected before the glucose injection were used to measure basal levels of mouse insulin and human resistin.

Hyperinsulinemic-euglycemic clamp. {#s12}
----------------------------------

Hyperinsulinemic-euglycemic clamp analysis was performed as described previously ([@B29]). Clamp studies were performed at 6 h after LPS (0.2 mg/kg) or saline intraperitoneal injection, and also at 10 days after the minipump subcutaneous implantation. Mice were fasted for 4 h, placed in restrainers, and administered a bolus injection of 5 μCi of \[3-3H\]glucose, followed by continuous intravenous infusion at 0.05 μCi/min. Baseline glucose kinetics was measured for 60 min, followed by hyperinsulinemic clamp for 120 min. A priming dose of regular insulin (16 mU/kg, Humulin; Eli Lilly, Indianapolis, IN) was given intravenously, followed by continuous infusion at 2.5 mU/kg/min. Tail blood glucose was measured by glucometer at 10-min intervals, and blood glucose was maintained at 120--140 mg/dL by a variable infusion rate of 20% glucose. 2-Deoxy-D-\[1-14C\]glucose (10 μCi) was injected 45 min before the end of the clamp, and blood samples were collected to estimate glucose uptake. The mice were killed, and liver, perigonadal WAT, and gastrocnemius muscle were excised, frozen immediately in liquid nitrogen, and stored at −80°C for subsequent analysis of glucose uptake and other analysis.

Statistics. {#s13}
-----------

Data are presented as means ± SEM. Changes of various parameters were analyzed with one-way ANOVA, followed by post hoc Tukey multiple comparison test or unpaired Student *t* test using Prism software (GraphPad Software, San Diego, CA). Values of *P \<* 0.05 were considered as statistically significant.

RESULTS {#s14}
=======

Generation of mice that express human resistin with human-like inducible regulation. {#s15}
------------------------------------------------------------------------------------

We generated a BAC that contains the human resistin gene plus all the DNA elements up to 21,300 bp upstream and 4,248 bp downstream relative to the human resistin start site ([Fig. 1*A*](#F1){ref-type="fig"}). Human resistin was basally expressed and markedly induced by LPS treatment of RAW.264 murine macrophages transfected with this BAC fusion construct ([Fig. 1*B* and *C*](#F1){ref-type="fig"}). To better understand the role of human resistin in the pathophysiology of inflammation and metabolism, we then derived transgenic mice on the C57BL/6 J *Rko* background using the BAC fusion construct (*BAC-Retn* mice). The expression pattern of human resistin in *BAC-Retn* mice was similar to that seen in humans, with the highest expression seen in bone marrow ([Fig. 1*D*](#F1){ref-type="fig"}) ([@B11]). Moreover, human resistin expression was dramatically induced in peritoneal macrophages isolated from *BAC-Retn* mice ([Fig. 1*E*](#F1){ref-type="fig"}).

![Generation and characterization of BAC-transgenic (*BAC-Retn*) mice. *A*: A BAC that contains the human resistin gene plus all the DNA elements up to 21,300 bp upstream and 4,248 bp downstream relative to the human resistin start site is used to generate the mice. The fusion construct was excised using *Not*I/*Bgl*II and injected into the pronucleus of fertilized C57BL/6 J mouse oocytes. *B*: Induction of human resistin gene by LPS (100 ng/mL) in transfected RAW.264 macrophages. *C*: LPS (100 ng/mL) induced secretion of resistin in transfected RAW.264 macrophages. *D*: Expression profile of human resistin in different tissues in *BAC-Retn* mice. *E*: LPS induced human resistin in vitro in peritoneal macrophages from *BAC-Retn* mice (*n* = 5 per group). Data are presented with the SEM. BAT, brown adipose tissue; BM, bone marrow; L. int, large intestine; PBMC, peripheral blood mononuclear cells; S. int, small intestine. \**P* \< 0.05, \*\**P* \< 0.01 vs. saline.](775fig1){#F1}

LPS-induced hypoglycemia is less severe in *BAC-Retn* mice. {#s16}
-----------------------------------------------------------

In the mice fed normal chow, there were no appreciable differences between *Rko* and *BAC-Retn* mice in serum levels of TGs, FFAs, ketone, adiponectin, or leptin. LPS increased serum alanine aminotransferase (ALT), FFA, and leptin levels in both groups and decreased serum total and high-molecular-weight adiponectin levels ([Table 1](#T1){ref-type="table"}). Circulating levels of human resistin increased about fivefold from baseline within 6 h after LPS injection in *BAC-Retn* mice, which was consistent with the robust increase in human resistin expression and secretion observed in blood mononuclear cells ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). As has been previously described ([@B33]), LPS injection caused hypoglycemia acutely. Although LPS induced similar increases in serum TNF-α and IL1β levels in *Rko* and *BAC-Retn* mice ([Fig. 2*C* and *D*](#F2){ref-type="fig"}), hypoglycemia was less severe in *BAC-Retn* compared with *Rko* mice (100 ± 6 vs. 77 ± 6 mg/dL, *P* \< 0.05; [Fig. 2*E*](#F2){ref-type="fig"}). Serum insulin levels were not different between groups (*P* = 0.32), suggesting human resistin attenuated hypoglycemia in acute endotoxemia via insulin resistance ([Fig. 2*F*](#F2){ref-type="fig"}).

###### 

Serum metabolic profile 6 h after LPS administration

  Variable                         Rko-Saline    BAC-Retn-Saline   Rko-LPS                                      BAC-Retn-LPS
  -------------------------------- ------------- ----------------- -------------------------------------------- ---------------------------------------------------------------------------
  Weight (g)                       29.4 ± 0.6    29.6 ± 0.8        29.5 ± 0.7                                   30.1 ± 0.5
  Triglyceride (mg/dL)             40.3 ± 5.2    32.6 ± 1.8        38.0 ± 3.0                                   55.9 ± 6.7[\*](#t1n1){ref-type="table-fn"}[†](#t1n2){ref-type="table-fn"}
  Cholesterol (mg/dL)              66.6 ± 5.3    67.5 ± 2.6        66.4 ± 2.5                                   72.1 ± 2.6
  FFAs (mEq/L)                     0.90 ± 0.05   0.85 ± 0.04       1.10 ± 0.05[‡](#t1n3){ref-type="table-fn"}   1.22 ± 0.13[\*](#t1n1){ref-type="table-fn"}
  Ketone (mg/dL)                   3.3 ± 0.5     5.5 ± 0.8         8.4 ± 1.0[‡](#t1n3){ref-type="table-fn"}     7.2 ± 0.6
  Alanine aminotransferase (U/L)   12 ± 1        14 ± 1            25 ± 2[\*](#t1n1){ref-type="table-fn"}       44 ± 3[\*](#t1n1){ref-type="table-fn"}[§](#t1n4){ref-type="table-fn"}
  Adiponectin (μg/mL)              25.7 ± 0.9    26.3 ± 2.0        21.3 ± 1.3[‡](#t1n3){ref-type="table-fn"}    20.2 ± 1.5[‡](#t1n3){ref-type="table-fn"}
  HMW adiponectin (μg/mL)          3.70 ± 0.13   3.45 ± 0.36       2.45 ± 0.28[‡](#t1n3){ref-type="table-fn"}   2.25 ± 0.17[‡](#t1n3){ref-type="table-fn"}
  Leptin (ng/mL)                   5.7 ± 1.0     4.8 ± 1.1         10.9 ± 1.7[‡](#t1n3){ref-type="table-fn"}    10.6 ± 1.4[‡](#t1n3){ref-type="table-fn"}

LPS (0.2 mg/kg) or normal saline (0.9%) was intraperitoneally injected in 12-week-old, normal-chow-fed *Rko* and *BAC-Retn* mice (*n* = 5--7 per group). Data are presented as means ± SEM.

BAC-Retn, BAC-transgenic; HMW, high-molecular-weight.

\**P* \< 0.01 vs. saline;

†*P* \< 0.05;

‡*P* \< 0.05;

§*P* \< 0.01 vs. *Rko*.

![Changes in resistin, cytokines, and glucose in acute endotoxemia in *BAC-Retn* mice. Acute LPS (0.2 mg/kg) or normal saline (0.9%) intraperitoneal administration to *Rko* (□) and *BAC-Retn* (■) mice (*n* = 5--7 per group). *A* and *B*: Human resistin was induced in response to LPS in vivo in *BAC-Retn* mice. *C* and *D*: Serum TNF-α and IL1β levels increased similarly in *Rko* and *BAC-Retn* mice. *E*: LPS-induced hypoglycemia is less severe in *BAC-Retn* than in *Rko* mice at 6 h after LPS injection. *F*: Serum insulin levels in 6 h after LPS injection. PBMC, peripheral blood mononuclear cells. Data are presented with the SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. saline; \#*P* \< 0.05 vs. *Rko*.](775fig2){#F2}

Insulin resistance in *BAC-Retn* mice in acute endotoxemia. {#s17}
-----------------------------------------------------------

To examine the role of human resistin in glucose homeostasis in acute endotoxemia, we performed hyperinsulinemic-euglycemic clamp studies after LPS or saline injection. Compared with saline injection, LPS acutely suppressed the basal rate of hepatic glucose production in *Rko* mice by 61%, and in *BAC-Retn* mice by 40% ([Supplementary Fig. 1*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). The glucose infusion rate required to maintain euglycemia was 31% lower in *BAC-Retn* than in *Rko* mice, indicating that the *BAC-Retn* mice were more insulin resistant during acute endotoxemia ([Fig. 3*A*](#F3){ref-type="fig"}). Hepatic insulin resistance in acute endotoxemia was manifested by a higher rate of glucose production (HGP) in *BAC-Retn* mice compared with *Rko* mice ([Fig. 3*B*](#F3){ref-type="fig"}). In support of this result, both glucose-6-phosphatase (G6pase) and PEPCK expression levels were slightly higher in *BAC-Retn* mice than in *Rko* mice under clamp studies in acute endotoxemia, although the differences did not reach statistical significance ([Supplementary Fig. 1*B* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). Although the whole-body rate of glucose disposal (Rd) was not different between both groups, insulin-stimulated glucose uptake in WAT was 46% lower in *BAC-Retn* mice ([Fig. 3*C--E*](#F3){ref-type="fig"}). Impaired glucose uptake in WAT in *BAC-Retn* mice was also consistent with significantly higher serum FFA levels compared with *Rko* mice, indicating less suppression of lipolysis by insulin during hyperinsulinemic clamp studies (0.13 ± 0.03 vs. 0.07 ± 0.03 mEq/L, *P* \< 0.05).

![Acute endotoxemia induces hepatic and adipose tissue insulin resistance in *BAC-Retn* mice. *A--C*: Hyperinsulinemic-euglycemic clamp analysis of *BAC-Retn* (■) vs. *Rko* (□) mice (*n* = 4 per group) in 6 h after LPS administration. *D* and *E*: Rate of insulin-stimulated glucose uptake in WAT (*D*) and skeletal muscle (*E*). *F*: Total ceramides content in liver. *G*: Correlation between hepatic ceramide content and hepatic glucose production (HGP) during the clamp study. Data are presented with the SEM. GIR, glucose infusion rate; Rd, whole-body rate of glucose disposal. \**P* \< 0.05 vs. saline; \#*P* \< 0.05 vs. *Rko*.](775fig3){#F3}

To understand the possible mechanism of hepatic insulin resistance, we next measured lipids content in liver. Compared with *Rko* mice, *BAC-Retn* mice had a 24% higher total ceramides content in liver ([Fig. 3*F*](#F3){ref-type="fig"}) during acute endotoxemia, with most ceramide species being elevated ([Supplementary Fig. 1*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). Moreover, there was a significant correlation between hepatic ceramide content and HGP during hyperinsulinemic clamp studies (*r* = 0.77, *P* \< 0.01; [Fig. 3*G*](#F3){ref-type="fig"}). However, there were no differences in hepatic diacylglycerol and TG levels between *Rko* and *BAC-Retn* mice ([Supplementary Fig. 1*E* and *F*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). Despite the changes in hepatic ceramide content, there were no differences in the expression of several genes involved in pathways of ceramide generation and salvage between *Rko* and *BAC-Retn* mice ([Supplementary Fig. 1*G*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)) ([@B34]).

Impaired glucose tolerance in *BAC-Retn* mice in chronic endotoxemia. {#s18}
---------------------------------------------------------------------

*BAC-Retn* mice were studied under chronic experimental endotoxemia to mimic the chronic inflammation of obesity and type 2 diabetes. Body weight and blood glucose of chronic LPS-infused mice significantly decreased initially, similar to the effect of acute endotoxemia described above, but recovered later ([Supplementary Fig. 2*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). During chronic endotoxemia, glucose tolerance in *BAC-Retn* mice was significantly impaired relative to the *Rko* mice ([Fig. 4*A*](#F4){ref-type="fig"}), while circulating resistin levels rose approximately fourfold in these mice ([Fig. 4*B*](#F4){ref-type="fig"}). Serum insulin, TNF-α and IL1β levels were not different in both groups, suggesting that human resistin is responsible for glucose intolerance in chronic endotoxemia ([Fig. 4*C*](#F4){ref-type="fig"}; [Supplementary Fig. 2*C* and *D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)).

![Impaired glucose tolerance and exacerbated inflammation in chronically endotoxemic *BAC-Retn* mice. *A*: With chronic LPS (2 mg/kg/day) subcutaneous infusion, *BAC-Retn* mice show impaired glucose tolerance compared with *Rko* mice (*n* = 5--7 per group). *B* and *C*: Serum resistin (*B*) and insulin (*C*) levels in *Rko* (□) and *BAC-Retn* (■) mice. *D* and *E*: Gene-expression analysis in liver (*D*) and skeletal muscle (*E*). Data are presented with the SEM. GTT, glucose tolerance test; RETN, human resistin. \**P* \< 0.05, \*\**P* \< 0.01 vs. saline; \#*P* \< 0.05, \#\#*P* \< 0.01 vs. *Rko*.](775fig4){#F4}

To explore the role of resistin on inflammation in chronic endotoxemia, we next performed gene-expression analysis. *BAC-Retn* mice had increased expression of proinflammatory cytokines as well as macrophage markers such as monocyte chemotactic protein-1 (MCP1) and F4/80 in liver and skeletal muscle ([Fig. 4*D* and *E*](#F4){ref-type="fig"}), indicating resistin exacerbated inflammation and promoted tissue infiltration of macrophages in chronic endotoxemia but not in WAT ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)). Although serum levels of TGs, FFA, and total and high-molecular-weight adiponectin decreased in chronic endotoxemia, there were no differences between the *Rko* and *BAC-Retn* mice ([Table 2](#T2){ref-type="table"}).

###### 

Serum metabolic profile in chronic endotoxemia

  Variable                         Rko-Saline    BAC-Retn-Saline   Rko-LPS                                      BAC-Retn-LPS
  -------------------------------- ------------- ----------------- -------------------------------------------- ---------------------------------------------
  Weight (g)                       28.0 ± 0.4    26.8 ± 0.8        26.2 ± 0.2                                   25.8 ± 0.3
  Triglycerides (mg/dL)            85.7 ± 5.4    70.2 ± 1.5        64.0 ± 6.3[\*](#t2n1){ref-type="table-fn"}   60.0 ± 2.8[\*](#t2n1){ref-type="table-fn"}
  Cholesterol (mg/dL)              80.8 ± 4.2    73.7 ± 1.2        72.3 ± 1.7                                   62.9 ± 5.2
  FFAs (mEq/L)                     0.77 ± 0.07   0.84 ± 0.08       0.41 ± 0.07[†](#t2n2){ref-type="table-fn"}   0.47 ± 0.04[\*](#t2n1){ref-type="table-fn"}
  Ketone (mg/dL)                   2.6 ± 0.3     3.2 ± 0.8         2.0 ± 0.3                                    1.9 ± 0.1[\*](#t2n1){ref-type="table-fn"}
  Alanine aminotransferase (U/L)   7 ± 1         8 ± 1             6 ± 1                                        7 ± 2
  Adiponectin (μg/mL)              25.2 ± 1.4    25.5 ± 1.2        15.9 ± 1.6[†](#t2n2){ref-type="table-fn"}    15.3 ± 0.7[\*](#t2n1){ref-type="table-fn"}
  HMW adiponectin (μg/mL)          3.60 ± 0.19   4.09 ± 0.99       1.57 ± 0.08[†](#t2n2){ref-type="table-fn"}   1.59 ± 0.11[\*](#t2n1){ref-type="table-fn"}

LPS (2 mg/kg/day) or normal saline (0.9%) was subcutaneously infused with a minipump to 10-week-old, normal-chow-fed *Rko* and *BAC-Retn* mice for 10 days (*n* = 5--7 per group). Data are presented as means ± SEM.

BAC-Retn, BAC-transgenic; HMW, high-molecular-weight.

\**P* \< 0.05;

†*P* \< 0.01 vs. saline.

Hepatic insulin resistance in *BAC-Retn* mice in chronic endotoxemia. {#s19}
---------------------------------------------------------------------

To determine the mechanism underlying the effect of humanized resistin induction on glucose homeostasis in chronic endotoxemia, we performed hyperinsulinemic-euglycemic clamp studies. The glucose infusion rate required to maintain euglycemia was significantly lower in *BAC-Retn* than in *Rko* mice ([Fig. 5*A*](#F5){ref-type="fig"}). Although Rd was not different, HGP was 60% higher in *BAC-Retn* mice, indicating that human resistin induced severe hepatic insulin resistance in chronic endotoxemia ([Fig. 5*B* and *C*](#F5){ref-type="fig"}). To understand the mechanism of hepatic insulin resistance, we examined gene-expression analysis in liver under clamp studies. TNF-α expression was approximately threefold higher in liver of *BAC-Retn* mice, suggesting resistin exacerbates inflammation in liver ([Fig. 5*D*](#F5){ref-type="fig"}). Expression levels of G6pase and PEPCK were also significantly higher in *BAC-Retn* mice compared with *Rko* mice (fourfold and twofold, respectively; [Fig. 5*E* and *F*](#F5){ref-type="fig"}), which is compatible with a higher rate of HGP in chronic endotoxemia. Measurements of lipids content in liver showed no differences in hepatic TG and total ceramides content between *Rko* and *BAC-Retn* mice ([Supplementary Fig. 4*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)).

![Hepatic insulin resistance in *BAC-Retn* mice in chronic endotoxemia. *A--C*: Hyperinsulinemic-euglycemic clamp analysis of *BAC-Retn* (■) mice vs. *Rko* (□) mice (*n* = 5--8 per group) in chronic endotoxemia. *D--F*: Gene-expression analysis in liver. Data are presented with the SEM. GIR, glucose infusion rate; HGP, hepatic glucose production; Rd, whole-body rate of glucose disposal. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. saline; \#*P* \< 0.05, \#\#*P* \< 0.01 vs. *Rko*.](775fig5){#F5}

DISCUSSION {#s20}
==========

Murine resistin is secreted by adipocytes, whereas human resistin is secreted by mononuclear cells. Although genetic and pharmacologic studies strongly support links between resistin, obesity, and insulin resistance in mice, the role of human resistin as a modulator of metabolism in inflammatory states is not well understood. The present finding that induction of human resistin alters glucose metabolism in endotoxemia clearly links human resistin to inflammation-induced insulin resistance. Therefore, this study provides much needed insight into the pathophysiologic role of human resistin in various inflammatory states associated with insulin resistance, ranging from sepsis to type 2 diabetes and atherosclerosis. In this respect, it is noteworthy that several epidemiologic studies have recently showed close relationships between resistin and type 2 diabetes, cardiovascular disease, and inflammatory markers ([@B17],[@B18],[@B21],[@B35]).

Early stages of sepsis and experimental endotoxemia are associated with hypoglycemia through increased glucose disposal by macrophage-rich tissues as well as decreased glucose production in humans as well as animals ([@B33],[@B36]--[@B38]). In line with previous reports, LPS administration acutely caused hypoglycemia in *Rko* and *BAC-Retn* mice, with similar robust increases in serum proinflammatory cytokines, which are known to cause hypoglycemia ([@B33],[@B36]). LPS increased serum leptin levels and decreased adiponectin, which can be explained by cytokine responses ([@B39]--[@B42]). During acute LPS-induced hypoglycemia, however, the induction of human resistin increased hepatic glucose production and decreased glucose uptake, thereby reducing the severity of hypoglycemia. Intriguingly, mice lacking resistin are more prone to fasting-induced hypoglycemia than wild-type mice ([@B9]), suggesting similar functions of resistin across species, albeit in different physiologic settings. Thus the human-specific expression pattern of resistin facilitates its function as a glucose counterregulatory hormone to mitigate hypoglycemia during acute endotoxemia. Of note, the metabolic effects of chronic endotoxemia in wild-type mice ([@B31]) are likely through a resistin-independent mechanism because murine resistin is not induced by LPS ([Supplementary Fig. 5*A*--*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-1416/-/DC1)) ([@B43],[@B44]), although it was recently reported to be induced by homocysteine, which is proinflammatory among other pleiotropic effects ([@B45]).

Animal studies on the acute effect of LPS on insulin sensitivity have yielded conflicting results ([@B46],[@B47]). In the setting of acute endotoxemia, we found that insulin sensitivity was enhanced in liver as well as in WAT of *Rko* mice and that human resistin abrogated this insulin-sensitizing effect of LPS, inducing insulin resistance. Our finding that hepatic ceramide content correlated with hepatic insulin resistance is consistent with a previous report ([@B48]). Ceramide has been shown to induce insulin resistance by inhibiting insulin signaling. Interestingly, TNF-α can acutely stimulate the accumulation of ceramide and various ceramide metabolites ([@B49]). Although there we did not detect differences in ceramide-related gene expression in liver of the *BAC-Retn* mice, the changes of hepatic ceramide content in acute endotoxemia could be due to changes in enzyme activity or to alterations in substrate flux.

During chronic endotoxemia, induction of human resistin promoted glucose intolerance and hepatic insulin resistance, suggesting its role as a link between innate immunity, inflammation, and insulin resistance. Epidemiologic studies provide strong evidence that chronic inflammation and obesity-induced insulin resistance are closely related ([@B50]--[@B53]). Experimental endotoxemia in humans, akin to states of infection and sepsis, also induces systemic insulin resistance as well as increased circulating resistin ([@B16],[@B37],[@B54]). Here we found that, in mice, chronic endotoxemia robustly induced inflammation in liver and skeletal muscle and was exacerbated by induction of human resistin. Our finding that human resistin promotes insulin resistance by inducing TNF-α and upregulating G6pase and PEPCK in liver are consistent with previous reports ([@B15],[@B55],[@B56]).

Although hepatic ceramide accumulation can at least partly explain hepatic insulin resistance in acute endotoxemia, tissue inflammation exacerbated by resistin, not hepatic ceramide, seems to be a plausible mechanism for insulin resistance in chronic endotoxemia. Recently, regulatory T-cells have been demonstrated to contribute to macrophage recruitment and adipose inflammation in obesity, and resistin has been shown to indirectly enhance regulatory T-cells ([@B57],[@B58]). Thus, T-cells, in addition to macrophages, may possibly be involved in the enhanced inflammation of the *BAC-Retn* mice. It remains unanswered how resistin functions in various tissues or cells, because the receptor for resistin has not yet been uncovered.

In summary, we have demonstrated that human resistin modulates glucose homeostasis under inflammation using a humanized resistin mouse model. Human resistin is induced in response to inflammation. Resistin attenuates endotoxemia-induced hypoglycemia by inducing insulin resistance in liver and WAT and promotes hepatic insulin resistance by exacerbating inflammatory responses in chronic endotoxemia. Increased inflammation is accompanied by increased infiltration of macrophages, which can, in turn, augment resistin induction. Thus, induction of resistin is expected to be a component of the pathophysiology of inflammation-induced insulin resistance in humans. The mouse model of humanized resistin expression reported here can be used to provide a better understanding and potential amelioration of the metabolic pathology of inflammatory states in humans.
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